Discussion
Direct damage to coronary arteries (intimal tears, atheromatous plaque fissuring or coronary artery rupture)' can occur following non-penetrating chest trauma. In general, the trauma is of severe magnitude; reports in the literature most commonly describe cases involved in road traffic accidents.2'3 In most cases underlying atheromatous coronary artery disease is presumed to be present, since angiographic imaging is generally not available. Where no atheromatous disease is evident, arterial occlusion resulting from intimal tears has been described.2 Cases where angiography is undertaken immediately after initial presentation appear to be rare. This case is unusual in that the chest trauma was of considerably smaller magnitude than is usually the case and occurred in a 'controlled' operative situation. Furthermore, coronary arteriography was undertaken within 30 minutes of the onset of symptoms and revealed extensive thrombus within the right coronary artery.
Thrombus formation in otherwise normal coronary arteries secondary to catecholaminemediated spasm is a rarely described phenomenon,4 but is unlikely to have been a factor in our patient since no electrocardiographic ST segment changes were apparent during the course of his general anaesthesia. Microscopic intimal tears, not visible on angiography, may have precipitated thrombus formation in this case. The relatively low magnitude of chest trauma suggests that this phenomenon may be a contributory factor in some cases of perioperative myocardial infarction following cardiothoracic surgery. Thus in patients presenting with electrocardiographic features of acute myocardial infarction following blunt chest trauma (including 'controlled' surgical trauma) early coronary angiography should be considered. He was commenced on prednisolone 20 mg and azathioprine 100 mg and sulphasalazine was stopped. Six months later dsDNA was negative and ANA positive to a titre of 1: 80. One year later the ANA was negative (though RF was 1: 160), the parotid swelling resolved and the systemic symptoms are well controlled on prednisolone 5 mg daily. C4 remains low at 0.14 g/l and IgA is less than 0.07 g/l.
Discussion Although Sjogren's syndrome and ulcerative colitis are both relatively common conditions, their coexistence has rarely been described.1 '2 IgA deficiency, the commonest form of primary immunodeficiency (occurring in 1/700 in the UK), is considered a risk factor of organspecific and systemic autoimmune disease.3 An association with systemic lupus erythematosus4 and juvenile rheumatoid arthritis5 has been established. In Sjogren's syndrome and ulcerative colitis few cases have been reported, however, reduced mucosal defence in IgA deficiency may be a simple predisposing factor to chronic submucosal inflammation and immunostimulation.
Sulphasalazine has been associated with lupus-like syndromes in patients treated for inflammatory bowel disease and, more recently, in rheumatic disease. 6 Sulphasalazine therapy is also an iatrogenic cause of selective IgA deficiency and in one study occurred in 3% of patients between eight and 20 weeks after starting treatment.7 It may have predisposed our patient to autoimmune disease, but we feel the persistence of low levels of IgA one year after drug withdrawal makes this less likely. In contrast to other forms of druginduced lupus, sulphasalazine-treated patients often develop high-affinity antibodies to dsDNA which disappear on drug withdrawal, may be associated with hypocomplementaemia and may take many months to resolve. This patient with Sjogren's syndrome was atypical in being a young male, possessing doublestranded DNA antibodies (normally associated with lupus), in the absence of extractable nuclear antigen (in particular Ro and La), the marked hypocomplementaemia and disappearance of auto-antibodies a year after drug withdrawal, though immunosuppressive therapy was continued throughout. It is conceivable that treatment with sulphasalazine may have contributed to the induction of autoimmunity in our patient, but to our knowledge no case of primary Sjogren's syndrome has been reported due to sulphasalazine therapy, although of course it often occurs secondary to systemic autoimmune diseases in patients on sulphasalazine. Furthermore, our patient's slow acetylator phenotype may represent an additional risk factor.
The persistent low C4 levels in the current case, even after apparent remission, is suggestive of a non-functioning C4 gene, with at least one C4 null allele. This is known to predispose to idiopathic and drug-induced systemic lupus erythomatosus as well as Sjogren's syndrome. 8 Furthermore, IgA deficiency is often found in association with C4 null alleles in patients with autoimmune disease, notably in the presence of HLA-A1, B8, DR3 haplotype, though our patient was not tissue typed. 
